Aptorum Group (APM)
Developing oncology, infectious disease, and diagnostic assets for unmet medical needs.
Aptorum Group Provides Update on DiamiR Biosciences Merger
Post-Merger company, Niki BioSolutions, Inc. , to Trade on Nasdaq Under Ticker "NIKI" Aptorum Group Announces 1-for-10 Reverse Share Split and Delaware Redomestication in Connection with the Merger The Merger is Expected to Close in July 2026 NEW YORK, NY, July 16, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ: APM) ("Aptorum Group" or "Aptorum" or "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that the closing of its merger with DiamiR Biosciences Corp.
Aptorum Group Provides Update on DiamiR Biosciences Merger
Post-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker “NIKI”
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Alidad Mireskandari, Ph.D.
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp.
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases.
Head-To-Head Survey: Aptorum Group (NASDAQ:APM) versus Catalyst Pharmaceuticals (NASDAQ:CPRX)
Aptorum Group (NASDAQ: APM - Get Free Report) and Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Risk and Volatility Aptorum Group has a beta
Aptorum Group Limited (NASDAQ:APM) Short Interest Up 41.4% in March
Aptorum Group Limited (NASDAQ: APM - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 12,292 shares, a growth of 41.4% from the March 15th total of 8,693 shares. Based on an average trading volume of 145,672 shares, the short-interest ratio
Andean Precious Metals Q4 Earnings Call Highlights
Andean Precious Metals (TSE: APM) used its fourth-quarter and year-end earnings call to highlight what management described as a "step change" in 2025 results, driven by record financial performance, strong free cash flow, and a significantly strengthened balance sheet. Executives pointed to contributions from both the San Bartolomé silver operation and the Golden Queen gold operation,
Aptorum Group Limited (NASDAQ:APM) Sees Significant Growth in Short Interest
Aptorum Group Limited (NASDAQ: APM - Get Free Report) was the target of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 11,553 shares, an increase of 14.8% from the February 12th total of 10,060 shares. Approximately 0.5% of the company's shares are sold short.
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease
NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB's automated APOE testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory.
Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 75.1%
Aptorum Group Limited (NASDAQ: APM - Get Free Report) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 2,681 shares, a decline of 75.1% from the December 15th total of 10,748 shares. Currently, 0.1% of the company's stock are short sold. Based on an
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online.
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp.
Andean Precious Metals: Record-High Gold-Silver Prices Pave The Way For A Mid-Tier Producer
Andean Precious Metals Corp. (APM:CA) is rated a Buy, driven by strong financials and robust growth strategies in gold and silver production. APM:CA benefits from rising precious metal prices, solid free cash flow, and a healthy balance sheet, supporting ongoing expansion and share buybacks. San Bartolomé's long-term ore agreement and Golden Queen's exploration program underpin production growth and extended mine life for APM:CA.
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconference/).
Why Is Nano-Cap Aptorum Stock Rallying On Thursday?
Aptorum shares trade higher on 168.16 million volume vs 3.25 million average. DiamiR gains CLEP approval for APOE Genotyping test in New York.
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, through its Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited clinical laboratory by licensed healthcare providers in New York State and nationwide.